Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis.

@article{Villa2012EnoxaparinPP,
  title={Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis.},
  author={Erica Villa and Calogero Camm{\`a} and Marco Marietta and Monica Luongo and Rosina Maria Critelli and Stefano Colopi and Cristina Tata and Ramona Zecchini and Stefano Gitto and Salvatore Petta and Barbara Lei and Veronica Bernabucci and Ranka Vukotic and Nicola de Maria and Filippo Schepis and Aimilia Karampatou and Cristian Caporali and Luisa Simoni and Mariagrazia Del Buono and Beatrice Zambotto and Elena Turola and Giovanni Fornaciari and Susanna Schianchi and Anna Ferrari and Dominique Charles Valla},
  journal={Gastroenterology},
  year={2012},
  volume={143 5},
  pages={
          1253-1260.e4
        }
}
BACKGROUND & AIMS We performed a randomized controlled trial to evaluate the safety and efficacy of enoxaparin, a low-molecular-weight heparin, in preventing portal vein thrombosis (PVT) in patients with advanced cirrhosis. METHODS In a nonblinded, single-center study, 70 outpatients with cirrhosis (Child-Pugh classes B7-C10) with demonstrated patent portal veins and without hepatocellular carcinoma were assigned randomly to groups that were given enoxaparin (4000 IU/day, subcutaneously for… CONTINUE READING